Wednesday 18th November 2020
Topic: Inventorship Considerations - An International Comparison
Date: Wednesday 18th November, 2020
Time: 4:00pm - 5:15pm GMT
Agenda to Include:
Panel discussion covering:
Dr Bernd Hutter – Morphosys AG (DE)
Bernd is Vice President and Head of Intellectual Property at MorphoSys AG, a German biopharmaceutical company engaged in the development of innovative biologicals to treat serious diseases. He spent the last 20 years in the world of patents and oversees all intellectual property matters of the organization from the lab bench to the market. Bernd spent his scientific life in the development of vaccines and drugs for tuberculosis, many years in South-East Asia.
He is also a consultant for several venture capital and biotech companies, helping both sides to facilitate investments and strategically align patent portfolios to business and business plans.
Dr Michael Roberts, Reddie & Grose LLP (UK)
Dr Michael A. Roberts is a partner at Reddie & Grose LLP, based in the firm’s Cambridge office. Michael’s IP practice is focused in the life sciences fields, and includes biotechnology, microbiology, molecular biology, genetic engineering, immunology, enzymology, pharmaceuticals, medical instruments and plant protection (including plant variety rights). Before joining the patent profession in 1999, he obtained a PhD in molecular genetics from the University of St Andrews and postdoctoral research experience at the John Innes Centre, Norwich.
Michael’s clients include small and medium-sized companies, multinationals, universities and overseas law firms. In addition to patent drafting and prosecution, he assists clients with due diligence and patent reports, notably for private or public fund raising, patent portfolio advice, and issues such as freedom to operate and patent validity. Michael is listed in the 2019 and 2020 IAM Patent 1000 directory of the world’s leading patent professionals.
Dave Hoffman, BitBio (US)
Dave Hoffman is a US-qualified patent attorney admitted to the state bars of California, Massachusetts, and the District of Columbia and registered to practice before the US Patent & Trademark Office. He is currently the Head of Intellectual Property at bit.bio in Cambridge, UK. Before that, he ran the intellectual property function at the Parker Institute for Cancer Immunotherapy in San Francisco, California, and before that worked in a variety of roles of increasing complexity and responsibility in both private practice and corporate legal departments.
Dave studied biology in college, completed a Ph.D. in Molecular, Cellular, and Developmental Biology at the University of Colorado at Boulder, worked as a postdoctoral researcher at CU-Boulder, the French National Institute of Health and Medical Research in Bordeaux, France, the University of California-Santa Cruz, and the NASA Ames Research Center, and earned a J.D. from Cornell Law School in 2004. His professional experience encompasses patent strategy including freedom to operate, non-infringement, and invalidity assessments, patent infringement litigation and appeals, patent prosecution and counseling, venture side due diligence, and negotiation of licenses, research collaborations, and other partnerships.
Maria Nichol, Galapagos
Maria Nichol is a European Patent Attorney and Chartered Patent Attorney. Sheread Natural Sciences (Pharmacology) at Cambridge, followed by a D.Phil. in Alzheimer’s disease research at the University of Oxford. She then moved into the patent profession in 2001. Working exclusively in-house for biotech companies, she started at Oxford GlycoSciences, then spent three years at Biotica Technology Limited. Since 2006, Maria has been responsible for IP strategy at Galapagos. Galapagos is a clinical-stage biotechnology company, specialized in the discovery and development of small molecule medicines with novel modes of action. Our ambition is to become a leading global biopharmaceutical company, focused on the discovery, development and commercialization of innovative medicines that will improve people's lives.